Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5803-5811

  Wilson, Thomas J ^a   Nannuru, Kalyan C ^a   Futakuchi, Mitsuru ^b   Sadanandam, Anguraj ^a   Singh, Rakesh K ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; CATHEPSIN K; COLLAGENASE 3; GELATINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; CATHEPSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; DNA MICROARRAY; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CATHEPSINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; SERINE ENDOPEPTIDASES;

EID: 48649097728     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5889     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrixmetalloproteina se cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904.
4. Eliceiri BP, Cheresh DA. Role of av integrins during angiogenesis. Cancer J 2000;6 Suppl 3:S245-9.
5. Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY. Processing of integrin av subunit by membrane type 1 matrixmetalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002;277:9749-56.
6. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-96.
7. Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007;8:245-57.
8. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988;251:293-9.
9. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
10. Ishikawa T, Kamiyama M, Tani-Ishii N, et al. Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001;32:84-91.
11. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrixturnover , and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
12. Ishibashi O, Niwa S, Kadoyama K, Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006;79:1657-60.
13. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24.
14. Ohshiba T, Miyaura C, Inada M, Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrixdegradation in bone destruction by breast cancer metastasis. Br J Cancer 2003;88:1318-26.
15. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
16. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
17. Fujisaki K, Tanabe N, Suzuki N, et al. Receptor activator of NF-κB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 2007;80:1311-8.
18. Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP. Catalytic properties of ADAM19. J Biol Chem 2003;278:22331-40.
19. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacologic criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor a convertase. J Biol Chem 2001;276:14665-74.
20. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:289-95.
21. Chavan V, Patil N, Karnik ND. Study of leukocytic hydrolytic enzymes in patients with acute stage of coronary heart disease. Indian J Med Sci 2007;61:73-82.
22. Komine K, Kuroishi T, Ozawa A, et al. Cleaved inflammatory lactoferrin peptides in parotid saliva of periodontitis patients. Mol Immunol 2007;44:1498-508.
23. Shimoda N, Fukazawa N, Nonomura K, Fairchild RL. Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. Am J Pathol 2007;170:930-40.
24. Campbell EJ, Owen CA. The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. J Biol Chem 2007;282:14645-54.